Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
27 Apr 2017 EMA Recommends Approval of Two Biosimilar Medicines – Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
26 Apr 2017 EMA Recommends Granting a Marketing Authorisation for Inotuzumab Ozogamicin Haematologic malignancies - Anticancer agents & Biologic therapy
25 Apr 2017 EMA Recommends Extension of Indications for Bevacizumab Gynaecologic malignancies - Anticancer agents & Biologic therapy
24 Apr 2017 EMA Recommends Extension of Indications for Nivolumab Genitourinary cancers - Cancer Immunology and Immunotherapy
19 Apr 2017 FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Certain Patients with Advanced Bladder Cancer Genitourinary cancers - Cancer Immunology and Immunotherapy
14 Apr 2017 FDA Allows Marketing of First Whole Slide Imaging System for Digital Pathology Pathology/Molecular biology
11 Apr 2017 European Commission Publishes Scientific Advices Related to Breast Implants and Health Bioethics, legal and economic issues
10 Apr 2017 FDA Grants Marketing Authorisation to Ipsogen JAK2 RGQ PCR Kit Personalised medicine - Haematologic malignancies
05 Apr 2017 EMA Publishes Framework and Action Plan for Closer Interaction with the Academic Community Bioethics, legal and economic issues
04 Apr 2017 NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
03 Apr 2017 FDA Grants Regular Approval to Palbociclib as Initial Endocrine Based Therapy Breast cancer - Anticancer agents & Biologic therapy
31 Mar 2017 FDA Grants Regular Approval to Osimertinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 Mar 2017 EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Dinutuximab beta Apeiron Central nervous system malignancies - Anticancer agents & Biologic therapy
29 Mar 2017 FDA Approves PARP Inhibitor Niraparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
28 Mar 2017 EMA Adopts a New Indication for Pembrolizumab Haematologic malignancies - Cancer Immunology and Immunotherapy